Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes
The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure.
The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure. This story matters for Finance & Markets readers tracking largecap. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. LargecapNews curates and briefs the finance & markets stories that matter. Our editorial policy →